IBMS 2nd Joint Meeting of the International Bone & Mineral Society Session List
Click here to search this conference.
Display sessions grouped by:
Track Session Code Speaker Date

Track: 

Free Communication
Opening Ceremony
 Symposium
 Workshop
 

Free Communication

030  Free Communication 1 
030-1  Contributions of the FTO gene to fracture risk 
030-2  A variant of human aromatase predicts increased circulating estradiol and bone health in post-menopausal women. 
030-3  Sexual Dimorphism in the Asssembly of Metaphysela Cortical and Trabecular Architecture 
030-4  Racial Differences in Macro and Micrarchitecture of the Appendicular Skeleton in Young Chinese and Caucasion Females 
030-5  Glucocorticoid-induced cortical bone loss is mediated by osteoblast-controlled activation of bone resorption 
030-6  Role of Bone Density and Clinical Risk Facctors in Mortality Risk Following All Osteporotic Fractures in Elderly Women and Men: An 18-year Prespective Study from Dubbo Osteoporosis Epidemiology Study 
030-7  In vivo quantification of age-related changes in human cortical bone thickness and porosity by HR-pQCT 
030-8  Pressentation of Copp Award to Stephen Krane 
070  Free Communication 2a 
070-1  Proteolytically processed repressor Gli3 inhibits bone formation by repressing BMP2 transcription in osteoblasts 
070-2  Cthrc1 is a positive regulator of osteoblastic bone formation 
070-3  Protein phosphatase magnesium-dependent 1A inhibits BMP signaling by stimulating Smad degradation independent of dephosphorylation at the carboxl termini 
070-4  AP-1 function in mesenchymal cell fate decision:The role of Ribosomal S6 Kinase and Fra1 
070-5  CREB induces BMP2 transcription in osteoblasts and CREB knockout reduces bone mass in mice 
080  Free Communication 2b 
080-1  Osteoblast IL-33 mRNA expression is regulated by PTH and IL-33 treatment causes both increased osteoblastic matrix mineralisation and reduced osteoclast formation invitro 
080-2  A dairy-based protein, calcium and Vitamin D supplement preserves trabecular bone and reduces falls in aged care residents 
080-3  Mechanical stress enhances osteoblast differentiation via canonical Wnt pathway 
080-4  Osteoblast specific Y1deletion enhance3s bone formation 
080-5  CNTF regulates mineralisation and plays critical sex-specific roles in bone formation 
120  Free Communication 3 
120-1  A Novel Small Thienoindazole-Derivative Compound Induces Chondrogenic Differentiation without Promoting Hypertrophy through Production of Runx1 
120-2  Osteomac are critical for optimal itramembranous bone formation in a tibial defect model of bone healing 
120-3  Regulation of adipogenesis by Zfp467, a novel zinc-finger protein 
120-4  Calcitonin attenuates the anabolic effect of PTH in young rats by rapid upregulation of sclerostin expression 
120-5  Ephrin B2 - EphB4 effects in osteoblast differentiation: role of RHOA signaling 
120-6  Role of neuropeptide Y in control of bone formation in leptin deficient mice 
120-7  Murine Oncostatin M (mOSM) regulates osetoblastic genes through a novel receptor 
120-8  OsteoMacs maintain the endosteal hematopoetic stem cell niche and participate in mobilization 
120-9  Presentation of Fleisch Award to Michael Rogers 
160  Free Communication 4a 
160-1  A fusion protein of parathyroid hormone (PTH) and a collagen binding domain shows superior efficacy and longer duration of action compared to PTH(1-34) as an anabolic bone agent in normal female mice 
160-2  Skeletal Anabolic Activity of Cannabinoid Receptor Agonists 
160-3  Effects of denosumab and alendronate on skeletal microarchitecture 
160-4  A Double-Blind, Placebo-Controlled, Phase III Study of Bazedoxifene/Conjugated Estrogens in Postmenopausal Women: Effects on Bone Mineral Density 
160-5  Efficacy of risedronate against hip fracture in patients with neurological diseases: A metaanalysis of randomized controlled trials 
170  Free Communications 4b 
170-1  Impact of alfacalcidol on bone mineral density (pQCT&DXA) of radius, tibia, spine and hip in postmenopausal alendronate treated women with reduced bone mass 
170-2  Effective osteoporosis treatments reduce mortality: a meta-analysis 
170-3  Lifestyle impact on lifetime bone loss in women and men. The Tromsø Study 
170-4  Do men and women have similar absolute risk of fracture? 
170-5  Fracture risk and access to funded osteoporosis treatments in New Zealand, Australia, UK and Canada 
210  Free Communication 5 
210-1  Hypoxia-inducible factor 2 (HIF-2 ) controls sequential steps of endochondral ossification during skeletal growth and osteoarthritis progression 
210-2  Identification of a Transcription Factor p63 for Joint Cartilage Formation by Analyses of Wnt9a and Gdf5 Promoters 
210-3  Loss of a single bim allele recovers the defective osteoclast function in bcl-2-/- mice but does not restore the anabolic action of PTH 
210-4  Micro RNA 18a regulates chondrocytic phenotype: Involvement of Ccn2/Ctgf as a major target gene 
210-5  A transcription factor Znf219 regulates chondrogenesis by forming a transcription factory complex with Sox9 
210-6  C/EBP / p57Kip2 Signaling Maintains Transition from Proliferation to Hypertrophic Differentiation of Chondrocytes during Skeletal Growth 
210-7  Androgen/androgen receptor directly acts in trabecular osteoclasts and cortical osteoblasts 
210-8  Nkx3.2 is an important mediator of hypoxia-induced chondrocytic differentiation 
250  Free Communication 6a 
250-1  CCN2/CTGF has anti-aging effects to protect articular cartilage from age-related degenerative changes 
250-2  Inhibitory Role of G q / PKC Signal in the Bone Anabolic Action of PTH 
250-3  Monocytes Control Mesenchymal Stem Cell Differentation Towards Osteoblasts 
250-4  Strontium ranelate amplifies the effects of PTH by improving the intrinsic tissue quality of the newly formed bone 
250-5  Vertebral fracture risk and alendronate effects in postmenopausal women assessed by CTbased nonlinear finite element analysis 
260  Free Communications 6b 
260-1  Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation and a novel non-UBA domain mutation (P364S) associated with increased NF- B signalling without loss of ubiquitin-binding 
260-2  Class IA phosphatidylinositol 3-kinases are indispensable for osteoclast function by regulating cytoskeletal organization and cell death 
260-3  DC-STAMP regulates bone homeostasis through cell-cell fusion of osteoclasts 
260-4  Ror2 signaling enhances osteoclast formation in physiological and pathological conditions 
260-5  Essential role of small GTPase Rac1 during limb development 
290  Free Communication 7a 
290-1  A randomized trial of balloon kyphoplasty and nonsurgical care for acute vertebral compression fracture 
290-2  Enzyme replacement therapy (ERT) for murine hypophosphatasia 
290-3  Association between Hyperglycemia and Fracture Risk in Non-diabetic Middle-aged and Older Australians: A National, Population based Prospective Study (AusDiab) 
290-4  Effects of Risedronate on Bone Marrow Adipocytes in Postmenopausal Women 
290-5  Skeletal dysplasia and lethality in mice lacking the mid-region, nuclear localization signal and cterminus of parathyroid hormone-related protein 
300  Free Communications 7b 
300-1  Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease 
300-2  Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression 
300-3  STAT3 induces osteoblastic bone metastases through up-regulating the expression of leptin and leptin receptors in the LNCaP human prostate cancer 
300-4  Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma 
300-5  Osteosarcoma metastasis: Evidence for ACP5 downregulation and osteoclast involvement 
310  Closing Ceremony & Awards 
Back to Top
Opening Ceremony

010  Opening Ceremony 
010-1  Indigenous welcome to the country   
010-2  Opening Plenary: Advances in understanding the molecular basis of bone remodelling: past, present and future   
010-3  Presentation of Rodan Fellowship to Fabienne Coury-Lucas   
010-4  Presentation of Gaillard Award to Gregory Mundy   
Back to Top
Symposium

020  Scientific Symposium 1 - Genetics 
020-1  Genetic Determinants of Locomotor Disease 
020-2  Genetic models of bone disease using ENU mutagenesis   
060  Symposium 2 - Mechanosensing 
060-1  Estrogen Receptor is a Critical Contributor at Multiple sites to Bones'' Adaptive Response to Mechanical Loading   
060-2  Winning the battle against childhood physical inactivity: the key to bone strength?   
090  Servier Symposium - Influencing bone remodelling and fracture risk 
090-1  Strontium Ranelate mode of action and effects on bone remodeling 
090-2  Do all agents have equal evidence? 
100  Sanofi-Aventis/ Procter & Gamble Symposium - Emerging data for osteoporosis management 
100-1  Broadening our knowledge through GLOW (Global Longitudinal study of Osteoporosis in Women)   
100-2  Differences between bisphosphonates: from mechanism of action to real life studies   
110  Scientific Symposium 3 - Bone & Cardiovascular Disease 
110-1  Skeletal stem cells and the microvascular system of tissue specific progenitors 
110-2  Arteriosclerosis and Bone Disease 
150  Symposium 4 — What's New in Osteoporosis 
150-1  Contribution of genetic factors to the individualized prognosis of fracture   
150-2  Future Management of Osteoporosis   
180  Amgen Symposium - RANK Ligand Inhibition from Bench to Bedside 
180-1  Cortical Bone: Neglecting Samson's Hair and Achilles' Heel 
180-2  RANK Ligand inhibition: Experiences from rodents to primates 
180-3  RANK Ligand inhibition in patients with postmenopausal bone loss 
190  Merck Symposium Osteoporosis: Highlighting the Progress of Novel Therapeutic Strategies 
190-1  Vitamin D in Health and Disease 
190-2  Treatment of Osteoporosis: New developments 
190-3  Chairman's Closing Remarks 
200  Scientific Symposium 5 - Osteoblasts 
200-1  Wnt and Hh signaling in skeletal development and homeostasis   
200-2  Neurogenic Regulation of Osteoblast Function   
240  Symposium 6 — Rare bone diseases 
240-1  Management of Osteogenesis Imperfecta   
240-2  Debate on Management of Paget''s Disease - "The Aim of Treatment is to Restore Normal Bone Turnover" 
270  Eli Lilly Symposium Postmenopausal health: new care strategies for women with multiple risks 
270-1  Role of bone quality in the pathogenesis of fragility fractures 
270-2  Teriparatide: the optimal choice for treatment of primary and secondary severe osteoporosis 
270-3  SERMs: chemoprevention of fragility fractures and invasive breast cancer 
280  Scientific Symposium 7 - Cancer & Bone 
280-1  Pathophysiology of Bone Metastasis 
280-2  Management of Cancer and Bone — Trials and Tribulations 
Back to Top
Workshop

040  Workshop 1 - Fracture Repair 
040-1  Biology of Fracture Healing and Effect of Osteoporosis Therapies   
040-2  Bone Morphogenetic Proteins (BMPs) and fracture repair   
040-3  Stem Cells and Fracture Repair 
050  Workshop 2 - Osteoclasts 
050-1  Nucleotides and regulation of bone cell function   
050-2  Cytokines that signal through gp130 and their roles in bone biology 
050-3  Sex Steroid Hormones Exhibit Osteoprotecitve Effects Through Nuclear Receptors Expressing In Bone Cells   
130  Workshop 3 - Fundamentals of Bone Quality 
130-1  On the Origins of Fracture Resistance and its Biological Degradation in Human Bone   
130-2  Nanoscale Deformation Mechanisms in Bone 
130-3  TGF-beta and Bone Matrix Material Properties 
140  Workshop 4 - Falls and Fractures 
140-1  Strategies for preventing falls in the elderly   
140-2  Bone Microarchitecture and Fracture Risk 
140-3  Vitamin D, Falls and Fractures What''s New?   
220  Workshop 5 - Osteocytes 
220-1  Functional morphology of osteocytes   
220-2  Molecular biology of osteocytes 
220-3  Osteocyte controls Pi homeostasis   
230  Workshop 6 - Vertebral Fractures 
230-1  Epidemiology of Vertebral Fractures 
230-2  New apoproaches to diagnosis of vertebral fractures   
230-3  Vertebroplasty and Kyphoplasty 
Back to Top